Free consultation:
(Mon. - Fri.: 09:00 - 18:00)

HAL Exoskeleton Lower Limb for the treatment of physical functions in rehabilitation.

HAL for Medical Use - Lower Limb Type is a medical device for the treatment of people with lower limb disorders. The product, which has been CE marked [CE 0197], complies with the requirements of the Medical Device Directives in the EU.

Your three tangible benefits:

  • All elements can be individually adjusted to the wearer
  • Pure control by the intention of movement
  • CE marking

Functions and advantages

Everything you need to know about the features and benefits of the HAL Exoskeleton Lower Limb for the treatment of physical functions in rehabilitation. need to know.

Description

HAL for Medical Use - Lower Limb Type is a medical device for the treatment of people with lower limb disorders. The product, which has been CE marked [CE 0197], complies with the requirements of the Medical Device Directives in the EU.

 

 

This product is designed to create a pathway for signals to reach the muscles to elicit a meaningful response through movement. This movement can be felt by the wearer and their brain, closing a signal loop that is important for inducing neuroplasticity, which is necessary for healthy motor function. Various product adaptations are also available to medical professionals to help the wearer achieve their intended movements more easily or work on correcting abnormal signals through specific therapeutic exercises that go beyond walking.

 

HAL for Medical Use - Lower Limb Type, is approved in the EU as a medical device for patients with symptom complex of musculoskeletal walking impairment [= MADS], such as spinal cord injury, traumatic brain injury, cerebrovascular disease and other diseases of the brain and neuromuscular systems

 

Elements of this product such as leg lengths, hip widths, and foot sizes can be precisely adjusted to fit all individuals, allowing for comfortable and effective treatment.

 

Like all other HAL systems, this product can be controlled by the wearer's intention to move. The product's non-invasive sensors can detect weak "bioelectric signals" that reflect the wearer's intention on the surface of the skin. Importantly, this unique system enables even patients with movement difficulties to perform the desired movements with their voluntary commands.

 

The product provides both the wearer and their healthcare provider with unique insight into the signal patterns generated by the wearer and important information such as the center of balance and phases of the gait cycle. This information helps shape the treatment course, which aims to maximize neuroplasticity and ultimately achieve greater independence.

 

An exoskeleton is attached to the outside of the body and provides the wearer with additional functional support. The exoskeletons used in the WALK AGAIN Center from the Japanese manufacturer Cyberdyne are made of particularly lightweight yet stable plastic and are known as Hybrid Assistive Limb or HAL® for short.

 

The robotic suit HAL® is the only approved system of its kind that captures the electrical signals from the brain via the skin surface of the lower extremities and provides motorized support. The movement is thus a controlled activity consciously desired by the patient. The positive feedback is sent back from the muscles to the brain. During the rehabilitation phase with HAL® therapy, the muscles are built up, the gait pattern improves significantly, becomes safer and walking aids can be reduced.

During HAL® therapy, impulses are sent back from the leg muscles to the brain. In this way, a so-called neuromuscular feedback is created, which causes an activation of the responsible brain area. The overall condition improves significantly.

For example, patients with paraplegia typically train with the system five times a week for 12 weeks. During this rehabilitation phase with the HAL® exoskeleton, many important treatment goals can be achieved. For example, leg muscles are built up, gait improves significantly and feels more secure.

Studies have shown the following additional improvements:

 

  • Increased walking speed
  • Reduced need for medical supplies
  • Improved skin feel
  • Spasticity reduction
  • Reduction of neuropathic pain
  • Strengthening of the musculature
  • Stimulation of the affected brain regions

Do you have any questions?

Can't find the answer to your question? Contact us.

Company information

Facts & Figures

The Japan-based company was founded back in 2003 and is one of the industry leaders in Japan. Cyberdyne has raised a total of ¥5.8B in 9 rounds of financing. The latest funding was raised on March 26, 2014 in a Venture - Series Unknown round. Cyberdyne is registered under the ticker TYO:7779 Cyberdyne is funded by 9 investors. Venture Labo Investment and Skystar Finance are the most recent investors. Cyberdyne has made 23 investments. The most recent investment was made on July 11, 2022 when LIFESCAPES raised 720 million yen. Cyberdyne has made 3 exits. Cyberdyne's most notable exits include Allm, Kringle Pharma, and Miraisens.

Company address

  • CYBERDYNE, INC.
  • 〒305-0818
  • 2-2-1, Gakuen-Minami
  • Tsukuba, Ibaraki Prefecture
  • 305-0818
  • Japan
{{ reviewsTotal }}{{ options.labels.singularReviewCountLabel }}
{{ reviewsTotal }}{{ options.labels.pluralReviewCountLabel }}
{{ options.labels.newReviewButton }}
{{ userData.canReview.message }}
Request more information

It applies our Privacy policy.

YouTube

By loading the video, you accept YouTube's privacy policy.
Learn more

Load video